Lanreotide

DEA Class; Rx

Common Brand Names; Somatuline Depot

Indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.

For the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic malignant neuroendocrine tumor (NET).

For the treatment of carcinoid syndrome, to reduce the frequency of short-acting somatostatin analog rescue therapy.

Hypersensitivity to lanreotide

• Abdominal pain (19%)
• Cholelithiasis (20%)
• Diarrhea (57%)
• Nausea (11%)
• Bradyarrhythmia (5% to 18% )
• Injection site reaction (subcutaneous depot, 6% to 22% ; intramuscular, up to 50% )
• Flatulence (up to 14% )
• Anemia (3% to 14% )
• Arthralgia (7%)
• Constipation (8%)
• Headache (7%)
• Loose stools (6%)
• Vomiting (7%)
• Hyper-/hypoglycemia/diabetes (7%)
• Sinus bradycardia (3%)
• Injection site pruritus
• Steatorrhea
• Aortic valve regurgitation
• Allergic skin reaction
• Mitral valve regurgitation
• Pancreatitis

Risk of reducing gallbladder motility, which could lead to gallstone formation; monitor periodically

Inhibition of insulin and glucagon secretion; may affect glucose regulation, which can lead to hyper-hypoglycemia; glucose monitoring is recommended; adjust antidiabetic treatment accordingly

Decreases in thyroid function reported; thyroid function tests are recommended where clinically indicated

Bradycardia, hypertension, and sinus bradycardia reported; use with caution in at-risk patients; initiate appropriate medical management in patients who develop symptomatic bradycardia

Pharmacological gastrointestinal effects of lanreotide may reduce the intestinal absorption of concomitant drugs; lanreotide may decrease the relative bioavailability of cyclosporine; concomitant administration of lanreotide and cyclosporine may necessitate the adjustment of cyclosporine dose to maintain therapeutic levels

Cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, and pancreatitis, and requiring cholecystectomy reported; if complications of cholelithiasis are suspected, discontinue therapy and treat appropriately

Use caution in renal/hepatic impairment, diabetes

Limited available data based on postmarketing case reports, use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes

There is no information available on presence of lanreotide in human milk, effects of drug on breastfed infant, or on milk production